• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions.

作者信息

Jacobson A F, Cronin E B, Stomper P C, Kaplan W D

机构信息

Division of Nuclear Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.

出版信息

Radiology. 1990 Apr;175(1):229-32. doi: 10.1148/radiology.175.1.2315486.

DOI:10.1148/radiology.175.1.2315486
PMID:2315486
Abstract

Scintigraphic, radiologic, and clinical follow-up findings were reviewed in cases in which bone scans (n = 301) showed one or two new abnormalities in patients with malignancy but no known metastases. Metastatic disease was confirmed for 25 of 231 scans (11%) with one new abnormality and for 17 of 70 scans (24%) with two new abnormalities. The prevalence of metastases was 0.06 to 0.13 for lesions in all regions of the skeleton, except the sternum (three of six) and the pelvis (10 of 32). On follow-up scans, in the absence of an interval change in therapy, 19 of 21 metastases became more intense, whereas most benign abnormalities either remained unchanged (47%) or resolved (41%). Benign lesions in the ribs, extremities, and pelvis generally resolved within 12-24 months, while most benign skull and spine abnormalities were still apparent after 35-58 months of follow-up.

摘要

相似文献

1
Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions.
Radiology. 1990 Apr;175(1):229-32. doi: 10.1148/radiology.175.1.2315486.
2
Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer.
J Nucl Med. 1990 Apr;31(4):387-92.
3
Bone secondaries in breast cancer: the solitary metastasis.乳腺癌的骨转移:孤立性转移灶
J Nucl Med. 1989 Aug;30(8):1318-20.
4
Clinical significance of solitary rib lesions in patients with extraskeletal malignancy.骨外恶性肿瘤患者孤立性肋骨病变的临床意义。
J Nucl Med. 1985 Oct;26(10):1140-3.
5
[Significance of skeletal scintigraphy for oncological practice].
Rontgenblatter. 1983 Oct;36(10):342-51.
6
Comparison of quantitative and visual detection of new focal bone lesions.新的局灶性骨病变定量检测与视觉检测的比较
J Nucl Med. 1985 Mar;26(3):230-6.
7
Reappraisal of the baseline bone scan in breast cancer.乳腺癌基线骨扫描的重新评估
J Nucl Med. 1988 Jun;29(6):1045-9.
8
[Multifocal breast neoplasm with bone involvement].[伴有骨受累的多灶性乳腺肿瘤]
Rev Med Brux. 1998 Dec;19(6):A501-2.
9
Clinical significance of solitary rib hot spots on bone scans in patients with extraskeletal cancer: correlation with other clinical manifestations.骨外癌症患者骨扫描中孤立性肋骨热点的临床意义:与其他临床表现的相关性
Clin Nucl Med. 2002 Aug;27(8):567-71. doi: 10.1097/00003072-200208000-00004.
10
Pattern and distribution of bone metastases in common malignant tumors.常见恶性肿瘤骨转移的模式与分布
Nucl Med Rev Cent East Eur. 2013;16(2):66-9. doi: 10.5603/NMR.2013.0037.

引用本文的文献

1
The need for bone biopsies in the diagnosis of new bone lesions in patients with a known primary malignancy: A comparative review of 117 biopsy cases.已知原发性恶性肿瘤患者新骨病变诊断中骨活检的必要性:117例活检病例的比较性综述
J Bone Oncol. 2018 Dec 18;14:100213. doi: 10.1016/j.jbo.2018.100213. eCollection 2019 Feb.
2
Risk of metastasis among rib abnormalities on bone scans in breast cancer patients.乳腺癌患者骨扫描中肋骨异常的转移风险。
Sci Rep. 2015 May 5;5:9587. doi: 10.1038/srep09587.
3
Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease.
钐153-乙膦二膦酸治疗疼痛性骨转移瘤的概述。
Rev Urol. 2004;6 Suppl 10(Suppl 10):S3-S12.
4
Staging for M disease.M病的分期
World J Surg. 1993 Nov-Dec;17(6):690-3. doi: 10.1007/BF01659076.